Immuron Limited (IMRN)

NASDAQ: IMRN · IEX Real-Time Price · USD
1.811
+0.051 (2.90%)
Feb 26, 2024, 12:09 PM EST - Market open

Company Description

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally.

The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.

The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection.

It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis.

Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Immuron Limited
Immuron logo
Country Australia
Founded 1994
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Steven George Lydeamore CPA, M.B.A.

Contact Details

Address:
62 Lygon Street, Level 3
Carlton, Victoria, C3 3053
Australia
Phone 61 03 9824 5254
Website immuron.com.au

Stock Details

Ticker Symbol IMRN
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001660046
CUSIP Number 45254U101
ISIN Number US45254U1016
SIC Code 2834

Key Executives

Name Position
Steven George Lydeamore CPA, M.B.A. Chief Executive Officer
Dr. Jerry Kanellos Ph.D. Chief Operating Officer
Flavio Palumbo Chief Commercial Officer
Phillip Allen Hains BBus(Acc), C.A., M.B.A. Chief Financial Officer and Company Secretary
David Lyon Head of Marketing

Latest SEC Filings

Date Type Title
Feb 21, 2024 6-K Report of foreign issuer
Feb 13, 2024 6-K Report of foreign issuer
Feb 9, 2024 6-K Report of foreign issuer
Jan 16, 2024 6-K Report of foreign issuer
Dec 22, 2023 6-K Report of foreign issuer
Dec 4, 2023 6-K Report of foreign issuer
Nov 28, 2023 6-K Report of foreign issuer
Nov 22, 2023 6-K Report of foreign issuer
Nov 21, 2023 6-K Report of foreign issuer
Nov 13, 2023 6-K Report of foreign issuer